Xeris Biopharma (NASDAQ:XERS) Research Coverage Started at Barclays

Barclays initiated coverage on shares of Xeris Biopharma (NASDAQ:XERS) in a research report report published on Monday, MarketBeat.com reports. The brokerage issued an overweight rating and a $9.00 price objective on the stock.

XERS has been the subject of a number of other research reports. Leerink Partners lifted their price target on Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Tuesday, August 19th. Piper Sandler raised their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, October 8th. Oppenheimer reissued an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.50.

Xeris Biopharma Trading Down 1.0%

NASDAQ XERS opened at $6.94 on Monday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -69.39 and a beta of 0.57. The firm’s fifty day moving average price is $8.03 and its two-hundred day moving average price is $6.77. Xeris Biopharma has a 1 year low of $3.14 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. On average, research analysts anticipate that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In other Xeris Biopharma news, insider John Patrick Shannon, Jr. sold 23,242 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $7.46, for a total transaction of $173,385.32. Following the transaction, the insider owned 2,643,153 shares in the company, valued at $19,717,921.38. This trade represents a 0.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.01, for a total transaction of $116,835.67. Following the completion of the sale, the insider directly owned 1,320,176 shares of the company’s stock, valued at approximately $9,254,433.76. The trade was a 1.25% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 56,576 shares of company stock worth $413,557. 6.47% of the stock is owned by corporate insiders.

Institutional Trading of Xeris Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. AlphaQuest LLC acquired a new position in shares of Xeris Biopharma during the 3rd quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after buying an additional 5,000 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Xeris Biopharma in the third quarter valued at approximately $68,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Xeris Biopharma in the third quarter valued at approximately $85,000. Finally, FORA Capital LLC acquired a new stake in Xeris Biopharma during the first quarter worth approximately $60,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.